Chargement en cours...
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a...
Enregistré dans:
| Publié dans: | Mol Cancer |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718690/ https://ncbi.nlm.nih.gov/pubmed/33276788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01290-7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|